海創藥業(688302.SH):目前PROTAC蛋白靶向降解技術平台已有多個在研品種
格隆匯5月31日丨有投資者向海創藥業(688302.SH)提問:請公司介紹PROTAC平台目前佈局產品?
海創藥業回覆:公司2016年開始進行PROTAC藥物研發,是國內較早進行PROTAC技術探索的企業,已合成多個目標蛋白配體、數百個Linker,整合了生物學、藥物化學、計算化學等學科,在解決行業難題PROTAC分子“化合物穩定性”、“口服生物利用度”、PK及CMC研發方面有豐富的技術經驗積累。目前PROTAC蛋白靶向降解技術平台已有多個在研品種,包括已進入臨牀階段的HP518以及針對ER、SHP2和AR剪切突變(AR-sv)等靶點的其他項目。公司積極推進在研PROTAC項目,力爭在全球性競爭中達到領先的地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.